Medetomidine

Research use only, not for human use.

A potent, highly selective α2-adrenoceptor agonist with Ki of 1.08 nM; used as both a surgical anesthetic and analgesic.

A potent, highly selective α2-adrenoceptor agonist with Ki of 1.08 nM; used as both a surgical anesthetic and analgesic.

Medetomidine (0-1 μM, 1 h) inhibits aldosterone release from the adrenocortical cell suspension.Medetomidine (10 nM) activates a kicking response in Cyprids.Medetomidine (1 μM) increases cellular cAMP production by activating β-like receptors in CHO cells.

Medetomidine (200 μg/kg, p.o. or i.m.) induces a sedation in cats.Medetomidine (20 μg/kg, i.v.) shows sedative and analgesic effects in dogs.Medetomidine (0.05-0.3 mg/kg, s.c.) protects against Diazinon-induced toxicosis in mice. Animal Model:Diazinon (75 mg/kg, orally)-induced toxicosis in miceDosage:0.05, 0.1 and 0.3 mg/kg Administration:Subcutaneous injection (s.c.), 15 min before Diazinon.Result:Protected the mice from the toxicity induced by Diazinon.Decreased the occurrence of Straub tail, excessive salivation and tremor. Increased the latencies to onset of tremor and death when compared with control.Animal Model:Dogs Dosage:20 μg/kg Administration: Intravenous injection (i.v.)Result:Showed sedative and analgesic effects.Increased in SAP, MAP, DAP, MPAP, PCWP, CVP, SVR, PVR, core body temperature.Decreased in HR, CO, CI, SV, SI, RR, pH.

——

Angiogenesis

Adrenergic Receptor

Adrenergic Receptor

Neurological Disease

——

86347-14-0

200.2795

C13H16N2

>98% (HPLC)

10 mM in DMSO

CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C

1H-Imidazole, 5-[1-(2,3-dimethylphenyl)ethyl]-

(-20℃)

With Ice Pack

≥ 2 years